TD Asset Management Inc Boosts Holdings in Waters Corporation $WAT

TD Asset Management Inc boosted its holdings in Waters Corporation (NYSE:WAT) by 12.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,024 shares of the medical instruments supplier’s stock after purchasing an additional 27,990 shares during the quarter. TD Asset Management Inc’s holdings in Waters were worth $74,960,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Integrated Wealth Concepts LLC boosted its position in shares of Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after acquiring an additional 30 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Waters by 5.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock worth $189,000 after purchasing an additional 35 shares in the last quarter. Penserra Capital Management LLC lifted its stake in Waters by 13.1% in the 2nd quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 38 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of Waters by 1.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock valued at $679,000 after purchasing an additional 41 shares during the last quarter. Finally, Clearstead Advisors LLC grew its position in shares of Waters by 7.5% during the third quarter. Clearstead Advisors LLC now owns 586 shares of the medical instruments supplier’s stock valued at $176,000 after purchasing an additional 41 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.

Wall Street Analysts Forecast Growth

WAT has been the topic of a number of research analyst reports. HSBC initiated coverage on Waters in a research report on Tuesday, January 27th. They issued a “buy” rating and a $460.00 target price on the stock. Barclays assumed coverage on Waters in a research report on Tuesday, February 10th. They set an “overweight” rating and a $400.00 target price for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a report on Wednesday, January 21st. Guggenheim reaffirmed a “buy” rating and set a $440.00 price target on shares of Waters in a research note on Tuesday, February 10th. Finally, Wolfe Research raised shares of Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 price objective for the company in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $393.84.

Waters Stock Performance

NYSE WAT opened at $322.38 on Friday. The business’s 50 day moving average price is $369.94 and its 200-day moving average price is $349.92. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15. The company has a market cap of $19.20 billion, a P/E ratio of 29.93, a P/E/G ratio of 2.20 and a beta of 1.18. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.01 and a current ratio of 1.73.

Waters (NYSE:WAT) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The company had revenue of $932.36 million during the quarter, compared to analyst estimates of $928.17 million. During the same period in the previous year, the firm earned $4.10 earnings per share. Waters’s quarterly revenue was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Sell-side analysts predict that Waters Corporation will post 12.86 earnings per share for the current year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.